C12Y 304/21104
Mannan-binding lectin-associated serine protease-2
Official title: Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
C12Y304/21104 (Mannan-binding lectin-associated serine protease-2) appears on 16 US grants and 38 published applications in this corpus.
Search patents in C12Y- Granted patents
- 16
- Published applications
- 38
- Assignees
- 9
- Inventors
- 45
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 4 |
| 2018 | 1 | 2 |
| 2019 | 0 | 2 |
| 2020 | 3 | 4 |
| 2021 | 2 | 4 |
| 2022 | 0 | 1 |
| 2023 | 1 | 3 |
| 2024 | 3 | 6 |
| 2025 | 0 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Mannan binding lectin serine peptidase 2 (MASP2) IRNA compositions and methods of use thereof18 Aug 2026US 12,709,751 B2Alnylam Pharmaceuticals, Inc.
- Methods for treating conditions associated with MASP-2 dependent complement activation14 May 2024US 11,981,749 B2Omeros Corporation
- Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant13 Feb 2024US 11,896,621 B2Omeros Corporation
- Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders30 Jan 2024US 11,883,493 B2Omeros Corporation
- Compositions for inhibiting MASP-2 dependent complement activation28 Mar 2023US 11,613,589 B2Omeros Corporation
- Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule10 Sep 2026US 2026/0265755 A1Argonaute Rna Limited
- A modified protein scaffold and use thereof9 Apr 2026US 2026/0098080 A1Evolveritas BiotechnolóGiai KorláTolt FelelosséGu TáRsasáG
- Masp-2-targetting antibodies and uses thereof15 May 2025US 2025/0154284 A1Inmagene Pte. Ltd.
- Conjugate24 Oct 2024US 2024/0352463 A1Argonaute Rna Limited
- Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders17 Oct 2024US 2024/0342278 A1Omeros Corporation
Most cited
By later US patents
- Methods for treating conditions associated with MASP-2 dependent complement activation60US 7,919,094 B2Omeros Corporation · 2011
- Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation40US 8,652,477 B2Omeros Corporation · 2014
- Masp-2, a complement-fixing enzyme, and uses for it19US 7,112,414 B22006
- Compositions for inhibiting MASP-2 dependent complement activation11US 9,011,860 B2Omeros Corporation · 2015
- Compositions for inhibiting MASP-2 dependent complement activation10US 9,475,885 B2Omeros Corporation · 2016